Key result
Elevated baseline erythropoietin above 23 mU/mL predicts increased mortality and heart failure hospitalization in CHF.
Why the study?
Considerable morbidity and mortality remain in CHF despite therapy, and the predictive value of circulating erythropoietin levels in clinically controlled CHF patients is unclear.
Do baseline circulating erythropoietin levels predict morbidity and mortality in patients with clinically controlled congestive heart failure?
Cohort (n=188)
Do baseline circulating erythropoietin levels predict morbidity and mortality in patients with clinically controlled congestive heart failure?
Elevated baseline circulating erythropoietin levels are a strong predictor of mortality and heart failure hospitalization in patients with chronic congestive heart failure.
No takes yet. Share an insight, caveat, or question.
EPO levels may aid risk stratification in stable CHF outpatients; leaves open incremental value beyond NT-proBNP pending validation.
George et al. (2005) conducted a cohort in Congestive heart failure (n=188). Circulating Erythropoietin (EPO) levels vs. Lower EPO levels was evaluated on Hospitalization due to CHF or mortality. Elevated baseline circulating erythropoietin levels (cutoff 23 mU/mL) strongly predicted mortality and heart failure hospitalization over 24 months in outpatients with chronic CHF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: